BridgeMD
New treatment option for Renal Cell Carcinoma
Official title Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
ClinicalTrials.gov ID: NCT06966024
What this study is testing
What is DCC-2812?
DCC-2812 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for renal cell carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
- Able to take oral medication
- If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the...
- Adequate organ function and electrolytes Key
You likely can't join if
- Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
- Impaired cardiac function
- Major surgery within 28 days of the first dose of study drug
The study team makes the final eligibility decision.
Where it's taking place
- Boston, Massachusetts, United States
- Ann Arbor, Michigan, United States
- Philadelphia, Pennsylvania, United States
- Nashville, Tennessee, United States
- Austin, Texas, United States
- San Antonio, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Boston, Massachusetts, United States; Ann Arbor, Michigan, United States; Philadelphia, Pennsylvania, United States; Nashville, Tennessee, United States; Austin, Texas, United States; San Antonio, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.